Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prevnar 13 Faces Two Disparate Challenges At Advisory Committee

This article was originally published in The Pink Sheet Daily

Executive Summary

Next-generation pneumococcal vaccine failed to show non-inferiority on several serotypes, and there is little scientific consensus about the criteria for its second proposed indication, otitis media.
Advertisement

Related Content

No Non-Inferiority, No Problem: FDA Advisory Committee Endorses Prevnar 13
Pfizer's Prevnar 13 Could Gain Edge With Vaccine Panel Review
Wyeth-Lederle To Submit Monthly Adverse Events Reports For Prevnar
Wyeth-Lederle To Submit Monthly Adverse Events Reports For Prevnar

Topics

Advertisement
UsernamePublicRestriction

Register

PS068754

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel